Stock Performance and Market Position
On the day it hit its new 52-week high, Artemis Medicare Services Ltd recorded a price of Rs.361.50, marking a notable peak in its trading history. Despite a slight dip of 0.49% on the day, the stock outperformed its sector by 0.75%, underscoring its resilience amid market fluctuations. The stock has been on an upward trajectory, gaining 4.4% over the last two consecutive trading days.
Artemis Medicare is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a strong bullish trend. The overall technical trend is classified as bullish, with key indicators such as MACD, Bollinger Bands, and On-Balance Volume (OBV) supporting this positive momentum.
Comparative Returns Against Benchmarks
The company’s stock has delivered market-beating returns across multiple timeframes. Over the past year, Artemis Medicare Services Ltd generated a remarkable 48.97% return, significantly outperforming the Sensex, which declined by 8.18% during the same period. Year-to-date returns stand at 30.17%, compared to the Sensex’s negative 12.27% performance.
Longer-term performance is equally impressive, with a three-year return of 161.39% versus the Sensex’s 12.26%, and a five-year return soaring to 862.48%, dwarfing the Sensex’s 28.23%. These figures highlight the company’s consistent ability to generate value for shareholders over extended periods.
Financial Strength and Growth Metrics
Artemis Medicare Services Ltd’s financial metrics reveal a company with solid fundamentals and healthy growth. The company boasts a low Debt to EBITDA ratio of 1.39 times, indicating a strong capacity to service its debt obligations. Operating profit has grown at an annual rate of 33.45%, reflecting robust operational efficiency and expanding profitability.
The company has reported positive results for ten consecutive quarters, demonstrating sustained earnings growth. Key profitability ratios include a Return on Capital Employed (ROCE) of 14.21% and a Return on Equity (ROE) of 11.3%, both indicative of effective capital utilisation. The debt-equity ratio remains conservative at 0.28 times, further underscoring financial stability.
Valuation and Dividend Profile
At the current price of Rs.352.75 (as of 09:35 AM on 10 September 2026), Artemis Medicare Services Ltd trades at a Price to Earnings (P/E) ratio of 48 times and a Price to Book Value (P/BV) of 6.01 times. The company’s PEG ratio stands at 2.91, reflecting the relationship between its price-to-earnings ratio and earnings growth rate.
Dividend metrics indicate a modest yield of 0.13%, with the latest dividend declared at Rs.0.45 per share and a payout ratio of 7.49%. The ex-dividend date was 10 July 2026. These figures suggest a balanced approach to rewarding shareholders while retaining earnings for growth.
Quality and Institutional Participation
The company is rated as a good quality entity based on its long-term financial performance. It has demonstrated a five-year sales compound annual growth rate (CAGR) of 18.93% and an EBIT growth rate of 33.45%. Institutional holdings are relatively high at 20.84%, indicating strong participation from professional investors.
Management risk is assessed as average, while growth and capital structure are rated good. The company maintains low leverage, with an average net debt to equity ratio of 0.06, and a tax ratio of 25.03%, consistent with industry norms.
Short-Term Financial Trends
Recent quarterly results reinforce the company’s positive trajectory. The half-yearly ROCE peaked at 14.21%, while the debt-equity ratio reached its lowest at 0.28 times. Operating profit to interest coverage ratio stood at a robust 8.74 times, indicating strong earnings relative to interest expenses.
Net sales for the quarter hit a high of ₹287.32 crores, with operating profit reaching ₹56.44 crores, representing 19.64% of net sales. Profit before tax less other income was ₹37.26 crores, and profit after tax was ₹31.31 crores, all marking record quarterly highs.
Risks and Considerations
One notable risk factor is the high percentage of promoter shares pledged, which stands at 44.53%. In volatile or declining markets, this could exert additional downward pressure on the stock price. Investors should be mindful of this aspect when analysing the company’s stock performance.
Technical Support and Resistance Levels
Key technical support is identified at the 52-week low of Rs.202.85, while immediate resistance lies near Rs.324.61, corresponding to the 20-day moving average. Additional resistance levels include Rs.281.78 (100-day moving average) and Rs.264.85 (200-day moving average). The all-time high of Rs.361.50 represents a significant resistance benchmark that the stock has now surpassed.
Volume and Market Activity
Delivery volumes have shown an upward trend, with a 7.6% increase over the past month and a substantial 76.99% rise in delivery volume on the day of the new high compared to the five-day average. On 9 September 2026, the stock recorded a volume of 4.07 lakh shares, accounting for 47.94% of total volume, indicating strong trading interest.
Conclusion
Artemis Medicare Services Ltd’s attainment of an all-time high price of Rs.361.50 on 10 September 2026 marks a significant milestone in its market journey. Supported by strong financial metrics, consistent earnings growth, and a bullish technical outlook, the company has demonstrated resilience and robust performance in the hospital sector. While certain risks such as promoter share pledging remain, the overall financial and operational indicators reflect a well-managed entity with a track record of delivering value to shareholders.
